Literature DB >> 6746149

Incidence of isoniazid acetylation phenotypes in North Indians.

R C Gupta, C R Nair, S K Jindal, S K Malik.   

Abstract

Isoniazid acetylation phenotypes were determined in 110 cases (55 of pulmonary tuberculosis and 55 of nontubercular chest diseases) by sulphadimidine acetylation test (Bratton and Marshall method). Cases with more than 65% of acetylated sulphadimidine in urine at 6th h were classified as fast acetylators, those with less than 50% as slow acetylators and others with values between 50-65% as intermediate acetylators. There were 39.09% fast, 46.36% intermediate and 14.55% slow acetylators. Possible factors for difference in results from other Indian studies have been discussed. Sulphadimidine acetylation showed no variation due to presence of disease, age, sex, religion, place of origin, height, weight and smoking habits. However, 79% of those who took alcohol regularly turned out to be fast acetylators.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6746149

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  3 in total

1.  Is there any difference between acetylator phenotypes in tuberculosis patients and healthy subjects?

Authors:  Hossein Khalili; Simin Dashti-Khavidaki; Mohsen Amini; Reza Mahjub; Mahboobeh Hajiabdolbaghi
Journal:  Eur J Clin Pharmacol       Date:  2010-03       Impact factor: 2.953

2.  Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children.

Authors:  Aparna Mukherjee; Thirumurthy Velpandian; Mohit Singla; Kunwar Kanhiya; Sushil K Kabra; Rakesh Lodha
Journal:  BMC Infect Dis       Date:  2015-03-14       Impact factor: 3.090

3.  Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India.

Authors:  Faisal Imam; Manju Sharma; Khalid Umer Khayyam; Mohammad Rashid Khan; Mohammad Daud Ali; Wajhul Qamar
Journal:  Saudi Pharm J       Date:  2020-04-19       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.